Castle Biosciences News and Activities
Presence
Castle Biosciences develops diagnostic tests for cancer and other diseases. It provides molecular testing services and decision support tools for doctors, hospitals, and healthcare providers.
Castle Biosciences products and services overview:
- Diagnostic testing
- Molecular diagnostics
- Cancer profiling
- Clinical decision support
Revenue: ~$331 million
Employees: 850
Headquarters: Friendswood, United States (USA)
Castle Biosciences is one of the...
Castle Biosciences is a company listed under the stock ticker CSTL (US).
Executives
View the org chart displaying its 31 main executives
Most searched biographies at Castle Biosciences
- Derek Maetzold, Director, President and Chief Executive Officer
- Miles Harrison, Director
- Tiffany Olson, Director
Create your alert
to follow the executive moves at Castle Biosciences.
Biotechnology
Castle Biosciences has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Castle Biosciences
- Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
- Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
- Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS
- Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
- Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
- Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
- DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
- Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
- Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
- Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
- View more press releases Close
Social media about Castle Biosciences
- Castle Biosciences on Wikipedia, Google News & Yahoo Finance
- Castle Biosciences on LinkedIn, X (Twitter) & YouTube
